Physician profile
Tarun Jain
NPI 1932156809
$1,273.64
in general payments reported to CMS, 2019-2025
12 companies · $111 in 2025
The $111 reported for 2025 was less than what a typical Reproductive Endocrinology provider received nationally (typical 2025 total: $140).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $475 · 2020: $71.03 · 2022: $172 · 2023: $120 · 2024: $324 · 2025: $111.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $361 · Travel and Lodging: $168 · Education: $25.46.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $361.42 |
| Travel and Lodging | $167.88 |
| Education | $25.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $431.58 | 2022-2025 | Cardiomems, Pressurewire, Gallant |
| Covidien LP | $249.31 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $216.57 | 2019-2020 | |
| Coopersurgical, INC. | $102.00 | 2022 | |
| Ferring Pharmaceuticals INC. | $63.65 | 2019-2023 | Menopur |
| Novo Nordisk INC | $52.51 | 2025 | Wegovy |
| Boston Scientific Corporation | $51.66 | 2022-2023 | Mamba |
| Glaxosmithkline, LLC. | $33.74 | 2022-2023 | Bexsero, Shingrix |
| Abiomed | $28.95 | 2020 | |
| Pfizer INC. | $16.59 | 2023 | |
| Bard Peripheral Vascular, INC. | $13.69 | 2023 | Atlas |
| Novartis Pharmaceuticals Corporation | $13.39 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tarun Jain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.